A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
* Evaluate the safety and tolerability of multiple doses of MEDI-538 by continuous IV infusion for 4 or 8 weeks in adult patients with B-cell NHL not eligible for curative therapy.
* Determine the maximum tolerated dose of MEDI-538 administered by continuous IV infusion.
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin
DRUG: MEDI-538|DRUG: MEDI-538|DRUG: MEDI-538
All endpoints will be analyzed descriptively. AEs and SAEs will be summarized by dose cohort, body system, severity, and relationship to MEDI-538 through 30 days after discontinuation of MEDI-538., 30 days after discontinuation of MEDI-538
The secondary endpoints of this study include measurement of the pharmacokinetics,immunogenicity, and antitumor activity of MEDI-538 in this patient population.
* Evaluate the safety and tolerability of MEDI-538 at doses of 5, 10, or 15 Î¼g/m2/24h by continuous IV infusion for 4 or 8 weeks in adult patients with B-cell NHL not eligible for
* Determine the MTD of MEDI-538 administered by continuous IV infusion for 4 or 8 weeks in adult patients with B-cell NHL not eligible for curative therapy.